Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoart… (NCT02844764) | Clinical Trial Compass
RecruitingPhase 2
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip
United States4,000 participantsStarted 2015-07
Plain-language summary
This is a prospective open-label clinical study of 50 patients to determine safety and treatment potential of autologous cell therapy for pain and inflammation associated with Osteoarthritis of the hip. Follow-up will consist of a larger sample including 4,000 patients.
Who can participate
Age range18 Years – 90 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients with indication of Osteoarthritis. Can be from degeneration or chronic injury.
✓. Patients range from 18-90 years of age.
✓. Patients must be able to comply with treatment plan, laboratory tests and periodic interviews.
✓. Patients with adequate renal function, Creatinine ≤ 1.5 mg/dl.
✓. Patients with adequate cardiac and respiratory function.
✕. Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study.
✕. Conditions/therapies/factors which could confound or interfere with the evaluation of pain/mobility including, but not limited to: